论文部分内容阅读
目的 :观察新型消化道动力药枸橼酸莫沙必利片治疗糖尿病胃轻瘫 (DGP)的疗效。方法 :116例确诊为DGP患者随机分为 3组 ,采用枸橼酸莫沙必利片治疗 4 8例 ,并与吗丁啉片、西沙必利片治疗者进行比较。结果 :枸橼酸莫沙必利片治疗 DGP疗效强于吗丁啉片 ,而与西沙必利片的疗效相当 ,但据报道西沙必利片在高敏患者中可出现 Q- T间期延长或导致尖端扭转性室性心动过速 ,枸橼酸莫沙必利片则无此电生理特征。结论 :枸橼酸莫沙必利片是一种比吗丁啉片、西沙必利片更有前途的治疗 DGP的新型促消化道动力药
Objective: To observe the efficacy of a new gastrointestinal motility drug, mosapride citrate tablets in treatment of diabetic gastroparesis (DGP). Methods: One hundred and sixty-one patients diagnosed with DGP were randomly divided into three groups. Forty-eight patients were treated with mosapride citrate and compared with those treated with domperidone and cisapride. RESULTS: The efficacy of mosapride citrate tablets in the treatment of DGP was stronger than that of domperidone tablets, which was comparable to cisapride tablets. However, it is reported that cisapride tablets may exhibit Q-T prolongation in hypersensitivity patients or Leading to torsades de pointes ventricular tachycardia, mosapride citrate tablets without this electrophysiological characteristics. CONCLUSIONS: Mosapride citrate tablets are a promising new drug for promoting digestive tract activity of DGP over dobutamine tablets and cisapride tablets